Global Markets Direct's, 'Thalassemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for thalassemia and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for thalassemia. Thalassemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
What is therapeutic effect:
“A therapeutic effect is a consequence of a medical treatment of any kind, the results of which are judged to be desirable and beneficial. This is true whether the result was expected, unexpected, or even an unintended consequence of the treatment. An adverse effect, on the other hand, is a harmful and undesired effect.
What constitutes a therapeutic effect versus a side effect is a matter of both the nature of the situation in which a treatment is used and the goals of treatment. There is no inherent difference between therapeutic and undesired side effects; both responses are behavioral/physiologic changes which occur as a response to the treatment strategy or agent. The most common nominal reason for preferring certain effects is avoiding death. However, those changes which are viewed as desirable, given the situation, are called therapeutic; those undesirable for the situation are viewed as harmful.”
Click the link for full report details-